U.S., April 1 -- ClinicalTrials.gov registry received information related to the study (NCT07503015) titled 'Phase 1 Study of HS-20152 in Healthy Participants' on March 25.
Brief Summary: This first-in-human, randomized, double-blind, placebo-controlled, single ascending dose study will evaluate the safety and tolerability of HS-20152, an investigational therapy targeting the complement pathway, in healthy adults. Secondary objectives include characterization of pharmacokinetics and pharmacodynamic effects on complement-related biomarkers.
Study Start Date: April 22
Study Type: INTERVENTIONAL
Condition:
Healthy Volunteers
Intervention:
DRUG: HS-20152
HS-20152: HS-20152 will be administrated as a single dose in four sequential dose c...